Admission glycaemia and outcome in patients with acute coronary syndrome by Müdespacher, Damaris et al.
Zurich Open Repository and
Archive
University of Zurich
Main Library
Strickhofstrasse 39
CH-8057 Zurich
www.zora.uzh.ch
Year: 2007
Admission glycaemia and outcome in patients with acute coronary syndrome
Müdespacher, Damaris; Radovanovic, Dragana; Camenzind, Edoardo; Essig, Manfred; Bertel, Osmund;
Erne, Paul; Eberli, Franz Robert; Gutzwiller, Felix
Abstract: Some studies of patients with acute myocardial infarction have reported that hyperglycaemia
at admission may be associated with a worse outcome. This study sought to evaluate the association
of blood glucose at admission with the outcome of unselected patients with acute coronary syndrome
(ACS). Using the Acute Myocardial Infarction and unstable angina in Switzerland (AMIS Plus) registry,
ACS patients were stratified according to their blood glucose on admission: group 1: 2.80–6.99 mmol/L,
group 2: 7.00–11.09 mmol/L and group 3: > 11.10 mmol/L. Odds ratios for in-hospital mortality were
calculated using logistic regression models. Of 2,786 patients, 73% were male and 21% were known to
have diabetes. In-hospital mortality increased from 3% in group 1 to 7% in group 2 and to 15% in group
3. Higher glucose levels were associated with larger enzymatic infarct sizes (p<0.001) and had a weak
negative correlation with angiographic or echographic left ventricular ejection fraction. High admission
glycaemia in ACS patients remains a significant independent predictor of in-hospital mortality (adjusted
OR 1.08; 95% confidence intervals [CI] 1.05–1.14, p<0.001) per mmol/L. The OR for in-hospital mortality
was 1.04 (95% CI 0.99–1.1; p=0.140) per mmol/L for patients with diabetes but 1.21 (95% CI 112–1.30;
p<0.001) per mmol/L for non-diabetic patients. In conclusion, elevated glucose level in ACS patients on
admission is a significant independent predictor of in-hospital mortality and is even more important for
patients who do not have known diabetes.
DOI: 10.3132/dvdr.2007.063
Posted at the Zurich Open Repository and Archive, University of Zurich
ZORA URL: http://doi.org/10.5167/uzh-4113
Originally published at:
Müdespacher, Damaris; Radovanovic, Dragana; Camenzind, Edoardo; Essig, Manfred; Bertel, Osmund;
Erne, Paul; Eberli, Franz Robert; Gutzwiller, Felix (2007). Admission glycaemia and outcome in patients
with acute coronary syndrome. Diabetes and Vascular Disease Research, 4(4):346-352. DOI: 10.3132/d-
vdr.2007.063
346
Abstract
Some studies of patients with acute myocardial infarc-tion have reported that hyperglycaemia at admissionmay be associated with a worse outcome. This study
sought to evaluate the association of blood glucose at
admission with the outcome of unselected patients with
acute coronary syndrome (ACS). 
Using the Acute Myocardial Infarction and unstable
angina in Switzerland (AMIS Plus) registry, ACS patients
were stratified according to their blood glucose on admis-
sion: group 1: 2.80–6.99 mmol/L, group 2: 7.00–11.09
mmol/L and  group 3: > 11.10 mmol/L. Odds ratios for
in-hospital mortality were calculated using logistic
regression models. 
Of 2,786 patients, 73% were male and 21% were
known to have diabetes. In-hospital mortality increased
from 3% in group 1 to 7% in group 2 and to 15% in group
3. Higher glucose levels were associated with larger enzy-
matic infarct sizes (p<0.001) and had a weak negative
correlation with angiographic or echographic left ventric-
ular ejection fraction. High admission glycaemia in ACS
patients remains a significant independent predictor of
in-hospital mortality (adjusted OR 1.08; 95% confidence
intervals [CI] 1.05–1.14, p<0.001) per mmol/L. The OR
for in-hospital mortality was 1.04 (95% CI 0.99–1.1;
p=0.140) per mmol/L for patients with diabetes but 1.21
(95% CI 112–1.30; p<0.001) per mmol/L for non-diabet-
ic patients. 
In conclusion, elevated glucose level in ACS patients
on admission is a significant independent predictor of in-
hospital mortality and is even more important for
patients who do not have known diabetes.  
Diabetes Vasc Dis Res 2007;4:346–52
doi:10.3132/dvdr.2007.063
Key words: acute coronary syndrome, admission
glycaemia, diabetes, gender, hyperglycaemia, outcome.
Introduction 
Diabetes mellitus is associated with an increased risk of car-
diovascular morbidity and mortality.1,2 Findings of a meta-
regression analysis suggest that even blood glucose levels
below the threshold for diabetes are related to raised car-
diovascular risk.3 Patients with a longer duration of diabetes
more frequently show signs of diabetic neuropathy that can
result in atypical symptoms during myocardial infarction.
Thus, diagnosis of an acute coronary syndrome (ACS) is
more difficult in these patients and initiation of adequate
therapy is often delayed.4 Among patients with acute
myocardial infarction (AMI), diabetes mellitus is associated
with higher mortality rates, both in-hospital5,6 and during
long-term follow-up.5,7 This is the case across the whole
spectrum of ACS.8 In that study, ACS patients with diabetes
had a higher risk of both death and re-infarction at 30 days
than those without diabetes, and the rates of death or re-
infarction at six months remained higher in the diabetic
group, whether they presented with ST-elevation myocardial
infarction (STEMI) or non-ST-elevation myocardial infarction
(NSTEMI).
High blood glucose levels in patients admitted for
ACS/AMI are common and are associated with an increased
risk of death in both patients with diabetes9-19 and patients
without diabetes.9-17,19 Admission hyperglycaemia is an even
stronger predictor for mortality in patients without a medical
history of diabetes.9,13,19
However, there is little information about differences in
outcome between men and women with hyperglycaemia on
admission for ACS/AMI. The aim of our study was to investi-
gate the association of admission glycaemia and outcome in
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patients admitted for ACS; furthermore, to examine if there
are differences in outcome not only between patients with
and without diabetes, but also between men and women
with hyperglycaemia at hospital admission.
Patients and methods 
The AMIS Plus Registry
In 1997, the Swiss Societies of Cardiology, Internal Medicine
and Intensive Care initiated a nationwide prospective reg-
istry to assess the diagnostic and therapeutic measures for
patients with AMI in Switzerland (AMIS). Academic and
non-academic hospitals participate voluntarily and provide
blinded data on these patients to the AMIS Plus Data Center
through an internet- or paper-based questionnaire of 140
questions. The Data Center controls and checks the data for
plausibility and cross-checks in case of queries. In the year
2000, patients with unstable angina were added to the reg-
istry. AMIS Plus is an industry-sponsored project, but the
supporting institutions do not play any role in the design of
the registry, data collection, analysis or interpretation. The
project is led by a Steering Committee comprised of mem-
bers of the founding societies. The registry was approved by
the Over-regional Ethical Committee for Clinical Studies and
the Swiss Board of Data Security.20,21 In March 2005 the
AMIS Plus Questionnaire was revised and admission gly-
caemia was included.
Patients
Patients enrolled in the AMIS Plus registry from March 2005
to March 2006 across the whole spectrum of ACS and with
valid data both on glycaemia at admission and history of dia-
betes were included. The spectrum covered AMI, defined
by characteristic symptoms and/or ECG changes and
enzymes (total creatine kinase [CK] or creatine kinase MB
fraction greater than twice the upper limit of normal), mini-
mal necrosis (the same, but the enzymes below twice the
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Table 1. Baseline characteristics and outcome of all ACS patients according to admission glycaemia groups 
Glucose levels (mmol/L) G1: 2.80–6.99 G2: 7.00–11.09 G3: > 11.10 p values
Number of patients (n=2,786) 1,299 1,117 370
Glycaemia on admission (mmol/L)
mean (SD) 5.9 (0.7) 8.4 (1.1) 15.4 (4.5) 0.001
median 6.0 8.2 13.7
Age min - max 28–95 27–96 37–93 0.01
mean + SD 65 (13) 67 (13) 69+13
median 65 68 71
Sex male (%) 993/1,299 (76.4) 795/1,117 (71.2) 252/370 (68.1)
female (%) 306/1,299 (23.6) 322/1,117 (28.8) 118/370 (31.9) 0.001
Past medical history
Hypertension (%) 728/1,259 (57.8) 661/1,074 (61.5) 267/354 (75.4) <0.001
Dyslipidaemia (%) 679/1,162 (58.4) 567/991 (57.2) 206/332 (62.0) 0.306
Smoking (current) (%) 477/1,246 (38.3) 342/1,042 (32.8) 106/329 (32.2) 0.011
Obesity (BMI > 30 kg/m2) (%) 194/1,151 (16.9) 219/999 (21.9) 83/305 (27.2) <0.001
Co-morbidities
Moderate-to-severe renal disease (%) 72/1,273 (5.7) 95/1,080 (8.8) 50/362 (13.8) <0.001
Diabetes (%) 114/1,299 (8.8) 215/1,117 (19.2) 244/370 (65.9) <0.001
Delay in minutes (median, interquartile range) 255 (120, 810) 210 (110, 600) 210 (103, 770) 0.013
(n=1,007) (n=926) (n=278)
CPR (%) 10/1,251 (0.8) 17/1,076 (1.6) 32/347 (9.2) <0.001
Killip class III/IV (%) 24/1,297 (1.9) 53/1,109 (4.8) 63/365 (17.3) <0.001
Symptoms on admission
Atypical (%) 136/1,277 (10.6) 145/1,097 (13.2) 75/359 (20.9) <0.001
STEMI (%) 615/1,298 (47.4) 689/1,117 (61.7) 215/370 (58.1) <0.001
Angiographic findings
Three-vessel disease (%) 300/985 (30.5) 277/848 (32.7) 89/230 (38.7) 0.053
Insulin (during initial treatment) (%) 93/1,277 (7.3) 176/1,084 (16.2) 208/364 (57.1) <0.001
Reperfusion <0.001 
Thrombolysis (%) 40/1,281 (3.1) 42/1,110 (3.8) 9/369 (2.4)
PCI primary (%) 772/1,281 (60.3) 729/1,110 (65.7) 188/369 (50.9)
Outcome
MACE 4.9 10.1 18.7 <0.001
In-hospital mortality 2.6 7.3 14.9 <0.001
Key: CPR = cardiopulmonary resuscitation; STEMI = ST segment elevation myocardial infarction; PCI = percutaneous coronary intervention;
MACE = major adverse cardiac events; BMI = body mass index
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upper limit of normal and troponin-positive) and unstable
angina (symptoms and/or ECG typical for ACS, normal
enzymes). Patients were defined as diabetic when diabetes
mellitus was reported in their past medical history, indepen-
dent of the kind of treatment they were receiving (oral
agents, insulin-treated or untreated). Co-morbidities were
documented using the Charlson Comorbidity Index.22 Other
risk factors previously diagnosed, treated and/or document-
ed in the patients’ medical history were also identified.
Patients were stratified into three admission glycaemia
groups: normal (G1: 2.80–6.99 mmol/L), intermediate (G2:
7.00–11.09 mmol/L) and elevated glucose concentrations
(G3: > 11.10 mmol/L). Baseline characteristics and out-
come were compared between these three groups. Within
G3 we compared short-term outcome of diabetic versus
non-diabetic patients and of male versus female ACS
patients. The end point was set as major adverse cardiac
events (MACE), including re-infarction, stroke and death or
in-hospital mortality. 
Statistical analyses
Data are presented as percentages for discrete variables
and as means (SD) and/or medians with interquartile range
for continuous variables. Differences in baseline character-
istics were compared using the t-test and the chi-squared
test. A p value <0.05 was considered statistically signifi-
cant.
Logistic regression models for predicting in-hospital mor-
tality were conducted using the Enter method with the fol-
lowing variables: age, gender, history of diabetes mellitus,
hypertension and renal disease, cardiopulmonary resuscita-
tion (CPR), Killip class, STEMI, systolic blood pressure, heart
rate on admission and primary percutaneous coronary inter-
vention (PCI). 
SPSS (Chicago, III, US) for Windows XP (version 13.0)
was used for all statistical analyses. 
Results 
Overall patient population
Of 2,924 ACS patients, 2,790 cases met the inclusion
criteria. Four patients with hypoglycaemia at admission
(< 2.80 mmol/L) were excluded because the numbers were
so small. Of the remaining 2,786 cases, 2,040 (73%) were
male and 746 (27%) female, 573 (21%) were known to have
diabetes and 2,213 (79%) were non-diabetic or their
diabetes status was unknown.
At hospital admission, the majority of ACS patients (47%)
had normal glucose levels (2.80–6.99 mmol/L, G1), 40%
intermediate levels (7.00–11.09 mmol/L, G2) and 13% had
clearly elevated glucose levels (> 11.10 mmol/L, G3).
Patient characteristics for the three groups are shown in table
1. Patients with increased glucose levels were more often
diabetic. They were older, more likely to be female and
obese, and more often had a past medical history of arterial
hypertension and moderate-to-severe renal disease. The fre-
quencies of a past medical history of dyslipidaemia were
similar in all three groups. The delay from onset of symptoms
to hospitalisation tended to be longest in G1. Patients in G3
needed CPR more often prior to arrival at hospital, and pre-
sented more often with Killip classes III/IV and atypical
symptoms compared to G1 and G2, respectively. Patients in
G2 and G3 suffered a STEMI more often than patients in G1.
Those in G1 were more likely to be current smokers. There
was a tendency towards a greater number of patients with
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Table 2. Predictors of in-hospital mortality at admission by logistic regression analysis in patients with ACS (n=2,525)
Odds ratio 95% CI Significance
Glucose levels per mmol/L 1.08 1.05–1.14 0.001
Age per year 1.07 1.05–1.10 <0.001
Gender 0.84 0.55–1.27 0.399
History of diabetes 0.86 0.53–1.39 0.545
History of arterial hypertension 0.89 0.72–1.75 0.602
Renal disease 2.23 1.38–3.62 0.001
Killip class II 1.57 0.99–2.49 0.056
Killip class III 1.83 0.88–3.82 0.106
Killip class IV 6.11 2.73–13.65 <0.001
STEMI 1.78 1.19–2.66 0.005
CPR 6.49 2.88–14.61 <0.001
Heart rate 1.00 0.99–1.01 0.553
Systolic blood pressure 0.98 0.97–0.99 <0.001
Percutaneous coronary intervention 0.47 0.30-0.75 0.002
Key: CI = confidence intervals; ACS = acute coronary syndromes; STEMI = ST segment elevation myocardial infarction; CPR = cardiopulmonary
resuscitation
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three-vessel disease in G3. G3 patients also received insulin
within 24 hours of admission more often compared to G1
and G2, respectively. G3 patients experienced more strokes
and cardiogenic shocks, whereas the frequencies of re-
infarction were similar in the three groups. The major
adverse cardiac events (MACE) rate was higher in G2 (10%)
and G3 (19%) compared with G1 (5%). Overall in-hospital
mortality was 6%, with differences among the groups: 3% in
G1, 7% in G2 and 15% in G3.
Diabetics versus non-diabetics
Overall in-hospital mortality was 10% in all diabetic patients
and 5% in all non-diabetic patients (p<0.001). Of the
patients with admission glycaemia > 11.10 mmol/L, 66% had
a previous diagnosis of diabetes and 34% did not. In this
hyperglycaemic group (G3), patients with previously diag-
nosed diabetes were older (70+12 vs. 68+14 years;
p<0.001), had significantly more risk factors such as arterial
hypertension (84% vs. 59%, p<0.001), dyslipidaemia (72%
vs. 45%, p<0.001) and obesity (32% vs. 18%, p=0.009), but
tended to be current smokers less often than non-diabetic
patients (29% vs. 39%, p=0.0065). Diabetic patients were
more often found to have three-vessel coronary artery disease
(45% vs. 27%, p=0.007) and previous coronary artery bypass
grafting (CABG; 9% vs. 3%, p=0.034) than non-diabetics.
The delay from onset of symptoms to hospitalisation was
longer in diabetic than in non-diabetic patients (270 min-
utes; interquartile range 115–810 vs. 180 minutes;
interquartile range 97–379 minutes, p=0.044), but there
was no difference in the frequency of atypical symptoms on
admission. Non-diabetics needed CPR significantly more
often prior to arrival at hospital (14% vs. 7%, p=0.030). They
tended to experience a STEMI more often (65% vs. 55%,
p=0.096) and to be admitted in heart failure Killip class
III/IV (23% vs. 15%, p=0.058). Reperfusion rates (thrombo-
lysis and primary percutaneous coronary intervention; PCI)
were similar, but patients without diabetes received insulin
significantly less frequently as part of the initial treatment
compared to patients with diabetes (29% vs. 72%,
p=<0.001). In patients without diabetes, the hospital
course was complicated more often by cardiogenic shock
than in patients with diabetes (15% vs. 7%; p=0.020). The
frequency of re-infarction and cerebrovascular insult was
similar between diabetic and non-diabetic patients. Non-
diabetics with admission glycaemia > 11.10 mmol/L had a
non-significantly higher MACE rate (25% vs. 16%; p=0.053)
and in-hospital mortality (20% vs. 12%; p=0.064) compared
to diabetic patients. 
Female versus male patients
Overall, in-hospital mortality was 6% in all men and 8% in
all women (p=0.075). Of the patients with admission gly-
caemia > 11.10 mmol/L, 252 (68%) were male and 118
(32%) female. The mean glucose levels were similar in both
genders (15.3 mmol/L vs. 15.5 mmol/L, p=0.821) while
male patients were on average eight years younger than
female patients (67 vs. 75 years, p<0.001). Frequency of
history of diabetes was similar in both genders (65% vs. 69%,
p=0.482) while female patients tended to have moderate-
to-severe renal disease more often (19% vs. 12%, p=0.074).
Males had significantly less arterial hypertension (70% vs.
86%, p=0.001) as a risk factor, but were more often current
smokers (40% vs. 15%, p<0.001) and overweight (77% vs.
60%, p=0.004) and more frequently had a history of CABG
(10% vs. 2%, p=0.004). The proportion with a history of
dyslipidaemia (63% vs. 59%, p=0.541) was similar in both
genders. In females, the delay from onset of symptoms to
hospitalisation was about twice as long as in males (358 min-
utes; interquartile range 120–939 minutes vs. 180 minutes;
interquartile range 96–642 minutes, p<0.001), and they
tended to have atypical symptoms more often (27% vs. 18%,
p=0.071) on admission. Male patients tended to present
more often with STEMI (61% vs. 52%, p=0.091) and need-
ed CPR significantly more frequently prior to arrival at hos-
pital (13% vs. 2%, p=0.001). Heart failure on admission
(Killip class III/IV) and complications (cardiogenic shock, re-
infarction and cerebrovascular insult) were, however, similar
in both male and female patients. Although males received
insulin significantly more often as immediate medication
(61% vs. 49%, p=0.031) and underwent primary PCI more
frequently (57% vs. 39%, p=0.10), they had a significantly
worse outcome. Male patients had a higher MACE rate (23%
vs. 11%; p=0.014) and higher in-hospital mortality (18%
vs.8%; p=0.007) than females. 
Glucose levels and infarct size
There was a highly significant, but weak, positive correlation
between glucose levels and maximum CK levels during
hospitalisation (n=2,747, correlation coefficient 0.18,
p<0.001), a weak negative correlation between glucose lev-
els and angiographic left ventricular ejection fraction (LVEF;
n=1,684, correlation coefficient -0.16, p<0.001) and a
weak negative correlation between glucose levels at admis-
sion and echographic LVEF (n=1,084, correlation coefficient
-0.27, p<0.001).
Predictors of in-hospital mortality at admission by logistic
regression analysis in ACS patients
In multivariate logistic regression analysis, higher admission
glycaemia remained an independent predictor of in-hospital
mortality (table 2). The unadjusted OR for in-hospital mor-
tality for glucose levels was 1.14 (95% CI 1.12–1.18) per
mmol/L, and adjusted OR was 1.08 (95% CI 1.05–1.14,
p<0.001). The OR for in-hospital mortality was 1.04
(0.99–1.1; p=0.140) per mmol/L for diabetic patients but
1.21 (112–1.30; p<0.001) per mmol/L for non-diabetic
patients; and 1.07 (0.97–1.15; p=0.109) for female patients
and 1.11 (1.05–1.17; p<0.001) for male patients. 
Discussion
The results of this study showed that patients presenting with
an ACS who are hyperglycaemic on admission represent a
high-risk population, even in the absence of an established
diagnosis of diabetes. Abnormal glucose metabolism during
the acute phase of AMI or ACS is common, and admission
hyperglycaemia is associated with increased short-term mor-
tality in both diabetic11-13,17-19 and non-diabetic11-13,17,19 patients.
Moreover, short-term mortality is predicted even more
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known diabetes.13,19
In-hospital mortality rates of all ACS patients in G1 (3%),
G2 (7%), and G3 (15%) in our study are in line with those
from another study that investigated the association of gly-
caemia on admission and outcome in patients admitted for
AMI (< 7.8 mmol/L: 1%, 7.8–11 mmol/L: 6%, > 11 mmol/L:
17%).17 Further, in-hospital mortality rates of diabetic (12%)
and non-diabetic patients (20%) in G3 are similar to those
observed by Wahab19 (diabetic > 11 mmol/L: 19%; non-dia-
betic > 11 mmol/L: 24%). 
In our study, increased glucose levels at admission in ACS
patients were associated with an increase of in-hospital mor-
tality of 8% per mmol/L, even after adjustment for covari-
ables. The impact of an elevated admission glucose level on
in-hospital mortality was even more important for non-dia-
betic than for diabetic ACS patients (interaction between
glucose levels and history of diabetes OR=0.87;95% CI
0.79–0.94). Similarly, 30-day mortality was predicted by
baseline glucose with a hazard ratio of 1.12 per 0.6 mmol/L
increase in patients without diabetes, but not in those with
diabetes.13 In addition, several studies have shown that
hyperglycaemia on admission is associated with long-term
mortality after AMI or ACS in both patients with9,10, 13-19 and
without9, 10,13-17,19 previously known diabetes. 
There are several possible causes of hyperglycaemia on
admission in patients with ACS, but it is not clear why it
should be associated with poor outcome. First, hypergly-
caemia on admission in non-diabetic ACS patients might
represent previously undiagnosed diabetes or pre-existing
impaired glucose tolerance. Wahab19 suggested that in non-
diabetic AMI patients, hyperglycaemia probably represents
unrecognised and therefore untreated diabetes, with many
years of uncontrolled elevated blood glucose levels resulting
in increased endothelial damage and thus greater risk for
macro- and micro-vascular morbidity. However, Tenerz23
found that in non-diabetic patients with AMI, increased
blood glucose on admission was not a reliable method of
establishing a diagnosis of diabetes and  follow-up was nec-
essary. Nevertheless, a substantial proportion of the non-
diabetic patients with even only slightly elevated admission
glycaemia (< 11.10 mmol/L) have undiagnosed diabetes or
impaired glucose tolerance,24 thus bearing an increased risk
of poor outcome after AMI/ACS.5-8
Secondly, hyperglycaemia on admission in ACS patients
might represent a response to acute and severe stress11
whereas increased catecholamine levels result in decreased
insulin secretion and increased insulin resistance. In the
CARDINAL study,13 individuals with higher baseline glucose
(upon diagnosis of AMI) had larger infarct sizes, determined
by CK-MB area under the curve. In the Zwolle trial25 there
was a clear association between LVEF, measured by equilib-
rium radionuclide ventriculography, and glucose levels in
non-diabetic patients with myocardial infarction. Higher glu-
cose levels on admission were correlated with lower LVEF.
These findings suggest that high glucose levels on admission
might be a marker of large myocardial infarctions and there-
fore also reflect severe stress and a high risk of poor progno-
sis. In our study, there was a significant positive correlation
between glucose levels and infarct size, measured as maxi-
mum CK, and a negative correlation between glucose levels
and LVEF measured on angiography and echocardiography. 
In the DIGAMI study,14 glycosylated haemoglobin, body
weight, heart rate and pulmonary rales on admission were
independently linked to admission hyperglycaemia. These
factors might reflect both previously unrecognised diabetes
and severe stress during the acute phase of AMI. 
In this study, CPR prior to arrival at hospital might have
played an important role in the clinical course of ACS. Of all
ACS patients, the highest frequencies of CPR were found in
G3 (in non-diabetics and in males). Hyperglycaemia in these
patients could have been a result of CPR and would there-
fore represent severe stress. However, it is also possible that
hyperglycaemia itself led to a worse clinical course and car-
diac arrest in the acute phase of ACS, necessitating CPR.
Since autonomic neuropathy in diabetic patients may mask
ACS, a larger proportion of hyperglycaemic diabetic patients
than hyperglycaemic patients without diabetes might have
died at home. However, if a high proportion of non-diabet-
ic hyperglycaemic patients were in fact undiagnosed (and
therefore untreated) diabetic patients, this might explain
why they needed CPR significantly more often prior to
arrival at hospital and why their hospital course was compli-
cated more often by cardiogenic shock. It remains unclear
whether hyperglycaemia is simply a marker of stress and of
poor prognosis or whether hyperglycaemia predisposes to a
worse outcome.9
In view of all these results, admission hyperglycaemia in
non-diabetics during the acute phase of ACS and its associ-
ation with poor outcome represents most likely a combina-
tion of previously undiagnosed diabetes, impaired glucose
tolerance, and a response to acute and severe stress.11
In ACS, STEMI has a higher mortality rate than NSTEMI.
In our study, patients with intermediate and high glucose lev-
els presented more often with STEMI than NSTEMI, and
non-diabetic males in G3 had the highest rate of STEMI,
which could have contributed to their poor outcome.
Outcome in STEMI is improved by reperfusion therapy, with
a significant benefit for primary PCI over fibrinolysis.13,26-28 In
this study, patients in G3 received primary PCI significantly
less frequently than those in G1 and G2, which might have
contributed to the worse outcome in this group. These find-
ings are in accordance with those of Straumann,17 who
found that in patients treated with PCI during the first 24
hours of an AMI, glucose levels > 11.0 mmol/L were a
strong predictor of 30-day mortality even after adjustment
for age, cardiogenic shock (Killip class IV), and TIMI 3 flow
after PCI. There was no evidence of a different effect of glu-
cose levels on survival between patients with and without
cardiogenic shock (Killip class IV) on admission. 
The DIGAMI study showed that immediate insulin-
glucose infusion followed by multi-dose subcutaneous insulin
reduced one-year mortality significantly in patients with AMI
and admission blood glucose concentrations > 11.0 mmol/L,
although the effect of this treatment on in-hospital mortality
was not significant.29 The second DIGAMI study did not
support this. However, compared to the first DIGAMI trial,
overall long-term glucose control was better in the second
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DIGAMI trial, which may have had a favourable influence on
outcome in the latter.30
Published risk score models for ACS to identify patients
at high risk for death and other major cardiac ischaemic
events have included a medical history of diabetes as a cat-
egorical variable.31,32 Straumann17 has stated that the categor-
ical variable ’elevated admission blood glucose level’ would
be a more powerful predictor of outcome than the variable
’medical history of diabetes’ in a modified risk score for
patients with ACS. 
There is little published information on the differences in
outcome between men and women with hyperglycaemia at
the time of admission for ACS. In the DIGAMI study, there
was no significant difference in long-term mortality between
male and female patients admitted for AMI with glycaemia
> 11.0 mmol/L, and female sex was not an independent,
unfavourable prognostic factor.15 In our study, overall in-hos-
pital mortality tended to be higher in women than in men
(p=0.075), while among the patients with admission gly-
caemia > 11.10 mmol/L, the MACE rate and in-hospital
mortality were significantly higher in men than in women,
even though men received primary PCI and insulin signifi-
cantly more often as immediate medication, and women
were older and had a history of hypertension more fre-
quently. In males, but not in females, increased glucose lev-
els at admission were associated with significant increases of
in-hospital mortality of 11% per mmol/L even after adjusting
for covariables. However, gender was not an independent
predictor of in-hospital mortality in multivariate logistic
regression analysis. 
Detection of high-risk patients by applying reliable
screening methods to all patients at admission for ACS is
indispensable in order to ensure rapid and appropriate treat-
ment and, consequently, decreased in-hospital mortality.
Our study has shown that hyperglycaemia on admission is a
strong risk factor for worse outcome in all patients admitted
with ACS. Measurement of glycaemia at hospital admission
may therefore be used as an early screening method to
detect high-risk patients. Blood glucose concentrations are
available within minutes of presentation, at a time when
other elements of risk prediction models such as elevated
serum markers of myocardial necrosis17,31,32 may still be nor-
mal. According to diabetes guidelines, all patients with coro-
nary artery disease and unknown diabetes status should be
screened for type 2 diabetes by an oral glucose tolerance test
(OGTT) that gives both fasting and two-hour post-load glu-
cose values, and by measuring HbA1C.33 In patients admitted
for ACS with significantly elevated blood glucose levels, nor-
moglycaemia should be aimed for as soon as possible by
means of insulin infusion. 
Glucose levels at admission for ACS could therefore be
used in order to detect high-risk individuals and to treat
them adequately. In order to detect diabetes or impaired
glucose homeostasis and therefore to prevent re-infarction
or death during follow-up, these screening methods could
be applied at discharge.
Study limitations
Differences in the use of drugs (aspirin, statins, β-blockers
and angiotensin-converting enzyme [ACE] inhibitors) are
known to influence the outcome of acute myocardial infarc-
tion and might have played a role in the effect on MACE and
the in-hospital mortality rate.34 In this study, we did not
analyse the influence of these drugs on MACE or on the in-
hospital mortality rate. 
Since we did not measure HbA1C at admission or fasting
glucose after recovery, we were unable to tell whether
hyperglycaemia at admission was caused by previously undi-
agnosed diabetes or by severe stress during the acute phase
of ACS. We used the medical history to determine a previ-
ous diagnosis of diabetes mellitus, thus it is likely that some
‘non-diabetics’ had unrecognised diabetes mellitus. 
It has recently been shown that there is a U-shaped rela-
tionship between admission blood glucose levels and poor
outcome after STEMI; moderate and severe hyperglycaemia,
and also hypoglycaemia, are associated with increased 30-
day mortality, irrespective of history of diabetes.35 Due to the
small number of hypoglycaemic patients in our study, we
were not able to verify a U-shaped relationship between
admission glycaemia and adverse outcome after ACS.
In conclusion, the data from this study have shown that
hyperglycaemia at admission is associated with a worse
outcome for all patients admitted with ACS. Complications
in general, cardiogenic shock, cerebrovascular insult and
in-hospital mortality increased with higher levels of blood
glucose. An elevated glucose level in ACS patients on
admission remained a significant independent predictor of
in-hospital mortality after adjustment for multiple risk fac-
tors known to be associated with increased in-hospital
mortality. The impact of a higher admission glucose level
on in-hospital mortality was even more important for non-
diabetic than for diabetic ACS patients. Thus, non-diabetic
patients with hyperglycaemia at admission were at special
risk. They may need particular attention at hospital admis-
sion, therefore more aggressive screening strategies should
be applied to all ACS patients in order to recognise these
high-risk patients. According to our results, hyperglycaemia
on admission clearly predicts a worse outcome and could
therefore be used as an early marker of high-risk individu-
als. These patients may benefit from an appropriate treat-
ment strategy, including strict glycaemic control. Further
studies to evaluate the effect of acute and intensive gly-
caemic control on reducing in-hospital mortality in patients
admitted for ACS are needed.
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